First Time Loading...

Graphite Bio Inc
NASDAQ:GRPH

Watchlist Manager
Graphite Bio Inc Logo
Graphite Bio Inc
NASDAQ:GRPH
Watchlist
Price: 22.26 USD 591.3% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

GRPH's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Graphite Bio, Inc. operates as a clinical-stage gene editing company. [ Read More ]

The intrinsic value of one GRPH stock under the Base Case scenario is 3.16 USD. Compared to the current market price of 22.26 USD, Graphite Bio Inc is Overvalued by 86%.

Key Points:
GRPH Intrinsic Value
Base Case
3.16 USD
Overvaluation 86%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Graphite Bio Inc

Backtest GRPH Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GRPH stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Graphite Bio Inc's business.

What risks and challenges
does Graphite Bio Inc face in the near future?

Summarize the latest earnings report
of Graphite Bio Inc.

Provide P/E
for Graphite Bio Inc and its competitors.

Financials

Balance Sheet Decomposition
Graphite Bio Inc

Current Assets 188m
Cash & Short-Term Investments 184.3m
Other Current Assets 3.8m
Non-Current Assets 435k
PP&E 321k
Other Non-Current Assets 114k
Current Liabilities 4.8m
Accounts Payable 250k
Accrued Liabilities 4.5m
Non-Current Liabilities 77k
Other Non-Current Liabilities 77k
Efficiency

Earnings Waterfall
Graphite Bio Inc

Revenue
0 USD
Operating Expenses
-73.1m USD
Operating Income
-73.1m USD
Other Expenses
-51.5m USD
Net Income
-124.7m USD

Free Cash Flow Analysis
Graphite Bio Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

GRPH Profitability Score
Profitability Due Diligence

Graphite Bio Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Graphite Bio Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

GRPH Solvency Score
Solvency Due Diligence

Graphite Bio Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Graphite Bio Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GRPH Price Targets Summary
Graphite Bio Inc

Wall Street analysts forecast GRPH stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GRPH is 7 USD .

Lowest
Price Target
Not Available
Average
Price Target
7 USD
69% Downside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GRPH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GRPH Price
Graphite Bio Inc

1M 1M
+557%
6M 6M
+798%
1Y 1Y
+816%
3Y 3Y
+20%
5Y 5Y
+20%
10Y 10Y
+20%
Annual Price Range
22.26
52w Low
2.18
52w High
22.26
Price Metrics
Average Annual Return -52.42%
Standard Deviation of Annual Returns 32.53%
Max Drawdown -94%
Shares Statistics
Market Capitalization 1.3B USD
Shares Outstanding 58 240 000
Percentage of Shares Shorted 0.28%

GRPH Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Graphite Bio Inc Logo
Graphite Bio Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.3B USD

Dividend Yield

0%

Description

Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 69 full-time employees. The company went IPO on 2021-06-25. The firm is developing a new class of therapies to cure a range of serious and life-threatening diseases. Its gene-editing platform allows to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. The firm's lead product candidate, GPH101, is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin (HgbA) expression. Its pipeline includes multiple programs, such as GPH102, for beta-thalassemia and GPH201, for X-linked severe combined immunodeficiency syndrome (XSCID), which is its gene replacement technology; GPH301 for Gaucher disease and an early-stage research program for alpha-1 antitrypsin (AAT) deficiency, which is its targeted gene insertion technology, and multiple undisclosed programs in both hematopoietic stem cells (HSCs) and other cell types.

Contact

CALIFORNIA
South San Francisco
201 Haskins Way, Suite 210
+16504840886.0
https://graphitebio.com/

IPO

2021-06-25

Employees

69

Officers

Academic Founder & Director
Dr. Matthew Porteus M.D., Ph.D.
President, CEO, COO, Principal Executive, Financial & Accounting Officer and Director
Ms. Kimberlee Cobleigh Drapkin CPA
Vice President of Communications & Investor Relations
Stephanie Yao
Chief Strategy Officer
Dr. Christine Garrett P.M.P., Ph.D.

See Also

Discover More
What is the Intrinsic Value of one GRPH stock?

The intrinsic value of one GRPH stock under the Base Case scenario is 3.16 USD.

Is GRPH stock undervalued or overvalued?

Compared to the current market price of 22.26 USD, Graphite Bio Inc is Overvalued by 86%.